Daiwa SB Investments Ltd. Boosts Position in Teladoc Inc (TDOC)

Daiwa SB Investments Ltd. increased its stake in shares of Teladoc Inc (NYSE:TDOC) by 52.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 24,048 shares of the health services provider’s stock after buying an additional 8,308 shares during the quarter. Daiwa SB Investments Ltd.’s holdings in Teladoc were worth $838,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Raymond James Trust N.A. lifted its stake in Teladoc by 36.2% in the third quarter. Raymond James Trust N.A. now owns 9,943 shares of the health services provider’s stock valued at $330,000 after acquiring an additional 2,643 shares during the last quarter. American International Group Inc. lifted its stake in Teladoc by 8.1% in the third quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock valued at $1,196,000 after acquiring an additional 2,697 shares during the last quarter. Swiss National Bank lifted its stake in Teladoc by 4.8% in the second quarter. Swiss National Bank now owns 59,500 shares of the health services provider’s stock valued at $2,065,000 after acquiring an additional 2,700 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Teladoc by 134.2% in the second quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after acquiring an additional 2,707 shares during the last quarter. Finally, Brown Advisory Inc. lifted its stake in Teladoc by 38.3% in the third quarter. Brown Advisory Inc. now owns 10,521 shares of the health services provider’s stock valued at $348,000 after acquiring an additional 2,915 shares during the last quarter.

In related news, CEO Jason N. Gorevic sold 100,000 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the transaction, the chief executive officer now owns 718,261 shares of the company’s stock, valued at $23,695,430.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jason N. Gorevic sold 20,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $32.10, for a total transaction of $642,000.00. Following the transaction, the chief executive officer now directly owns 838,261 shares in the company, valued at approximately $26,908,178.10. The disclosure for this sale can be found here. Insiders sold 210,000 shares of company stock valued at $6,889,350 over the last 90 days. 4.47% of the stock is owned by corporate insiders.

A number of analysts have issued reports on TDOC shares. KeyCorp reiterated a “buy” rating and issued a $37.00 target price on shares of Teladoc in a research note on Sunday, September 17th. Robert W. Baird cut shares of Teladoc from an “outperform” rating to a “neutral” rating and lifted their target price for the company from $14.00 to $36.00 in a research note on Monday, September 18th. Zacks Investment Research upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Cantor Fitzgerald reiterated a “hold” rating and issued a $31.00 target price on shares of Teladoc in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $42.00 target price on shares of Teladoc in a research note on Friday, September 29th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $39.31.

Shares of Teladoc Inc (NYSE:TDOC) opened at $32.65 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 5.08. Teladoc Inc has a one year low of $15.65 and a one year high of $38.40. The firm has a market cap of $1,980.00 and a price-to-earnings ratio of -22.52.

Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 29.70% and a negative net margin of 45.64%. The firm had revenue of $68.70 million during the quarter, compared to analyst estimates of $67.53 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. Teladoc’s quarterly revenue was up 112.0% compared to the same quarter last year. research analysts anticipate that Teladoc Inc will post -1.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Daiwa SB Investments Ltd. Boosts Position in Teladoc Inc (TDOC)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/13/daiwa-sb-investments-ltd-boosts-position-in-teladoc-inc-tdoc.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

What are top analysts saying about Teladoc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teladoc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit